Alcon AG vs Wahed FTSE USA Shariah ETF — how do they compare? Alcon AG trades at $75 (market cap $36.44B), while Wahed FTSE USA Shariah ETF trades at $72.96. The key difference: Alcon AG pays a 0.48% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | HLAL | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $73.60 |
52-Week Low | $62.02 | $55.52 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
HLAL trades at $72.95, showing minimal daily movement with a slight decline of 0.03%. Technical indicators signal a bullish trend based on moving averages, though oscillators are neutral. The stock lacks recent fundamental data, with key ratios like P/E and P/S unavailable. A small dividend of $0.02 is scheduled for June 2026, but no recent earnings or cash flow updates are present.
The outlook is mixed due to incomplete financials; technical strength suggests potential upside, but fundamental opacity poses risks. Investors face uncertainty without current revenue or profit metrics, requiring caution until updated SEC filings or analyst reports emerge to assess valuation and growth prospects accurately.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →